BioCryst Pharmaceuticals Hits New 52-Week Low at $6.00

BioCryst Pharmaceuticals, Inc. has reached a new 52-week low, trading at USD 6.00 as of October 14, 2025. This marks a significant decline for the small-cap company, which operates within the Pharmaceuticals & Biotechnology industry. Over the past year, BioCryst has experienced a performance dip of 1.53%, contrasting sharply with the S&P 500's gain of 14.44%.
The company's market capitalization stands at USD 1,719 million, and it currently does not offer a dividend yield. Financial metrics indicate a challenging landscape, with a negative book value and a debt-to-equity ratio of -1.11. Despite these hurdles, BioCryst reported a notable increase in operating profit, growing by 159.49% in its latest quarterly results. The company has also maintained a streak of positive results for 11 consecutive quarters, with operating cash flow reaching its highest at USD 16.57 million.

However, the stock's performance has been impacted by a decrease in promoter confidence, as stakeholders have reduced their holdings by 1.48% in the last quarter. This combination of factors contributes to a complex outlook for BioCryst Pharmaceuticals as it navigates its current market position.